68 results about "Immuno histochemistry" patented technology

Presented herein are systems, methods, and non-transient computer readable media for determining predicted response scores of subjects. A computing system may identify a first feature set for a first subject to be administered with immunotherapy to address a condition. The first feature set may include one or more of: (i) a first radiological feature identified in a tomogram of a section associated with the condition in the first subject, (ii) a first immunohistochemistry (IHC) feature derived from an image of a sample associated with the first subject, and (iii) a first genomic feature obtained from gene sequencing of the first subject for genes associated with the condition. The computing system may apply the first feature set to a model. The computing system may determine, from applying the first feature set to the model, a predicted score identifying a response to the immunotherapy to be administered to the first subject.

Techniques for using combination stain types for machine learning models for digital pathology are described herein. In an example, a system accesses a first image of a sample comprising an immunohistochemistry (IHC) stain for a biomarker. The system accesses a second image of the sample comprising a hematoxylin and eosin (H&E) stain for nuclei. The system can segment tissue regions in the one or more first images and the second image, partitions the tissue regions in the one or more first images and the second image, and extracts features from the set of tiles using a feature extractor. The system can generate, by a machine-learning model, an output classification indicating a first phenotype based on the features extracted from the set of tiles. The machine-learning model can include one or more classifiers and an aggregation model that provides an aggregated output for the set of tiles.

Injectable compositions and methods of preparation, as well as therapeutic uses, of induced pluripotent stem cell (iPSC)-derived notochordal cell (iNC)-loaded microgels are provided. Microfluidic on-chip platform can be utilized to prepare microgels (or microgel particles / spheres) formed from block copolymers that exhibit reverse thermal gelation, so as to encapsulate iNCs. Also provided are preconditioned iNC-loaded microgels and iNCs in bulk hydrogel. Cell purity, identity, viability, sterility, and the stability of microencapsulated iNCs have been evaluated. Safety and efficacy of the compositions as therapeutic candidates has been tested via intradiscal injection in animal models of intervertebral disc (IVD) degeneration and discogenic low back pain. Biobehavioral testing, MRI, and immunohistochemical analyses were utilized to evaluate the regenerative potential and reproducibility of the compositions as therapeutic candidate. Single cell RNA sequencing of the treated IVDs may also reveal mechanism of action of the compositions.

The invention belongs to the technical field of immunohistochemical detection, and discloses a modified composite sealing buffer solution as well as a preparation method and detection application thereof. The modified composite blocking buffer solution comprises a basic buffer system, a composite blocking agent, a nonionic detergent, an endogenous interferent blocking agent and an antibody stabilizer, wherein the basic buffer system provides a stable pH environment and ionic strength; the composite sealing agent firstly occupies a shielding site, and the background is lowered; the nonionic detergent destroys hydrophobic interaction, effectively elute and loosen adsorbed molecules, and promote dissolution of components with relatively strong hydrophobicity; the endogenous interferent blocker can be combined with a receptor firstly, so that non-specific combination of an antibody and the receptor is blocked, and the problem of specific background is solved; the antibody stabilizer can protect the activity of the detection reagent and maintain the stability, and the obtained modified composite sealing buffer solution and the kit thereof have the advantages of multiple cooperative sealing mechanisms, prospective blocking of endogenous interference, improvement of the stability, compatibility and high efficiency of the antibody and the like.

The invention relates to the technical field of medical data processing, and discloses a cancer immunotherapy prognosis prediction method, system and equipment based on CD8 + T cell density in a necrotic area and a medium. The method comprises the following steps: firstly, extracting pathological features on a CD8 immunohistochemical staining (IHC) slice image of tumor tissue of a to-be-detected person after neoadjuvant immunotherapy by using a multi-scale feature extraction model, and then carrying out regional division on the CD8 IHC slice image by using a regional classification model to obtain a necrotic region; then, the CD8 + T cells in the necrotic area are recognized and counted through the target recognition model, the cell density of the CD8 + T cells in the necrotic area is rapidly obtained, and finally, the EFS of the person to be detected is accurately predicted based on the cell density of the CD8 + T cells in the necrotic area. According to the method, efficient and high-precision EFS prediction can be carried out only through the CD8IHC slice image of the tumor tissue, and a doctor can make a proper diagnosis and treatment plan for a patient according to a prediction result.

The application discloses a marker for determining the severity of IgAN kidney tissue lesions and application thereof, and inventors find that ACTN4, ACADS and COL1A1 are significantly differentially expressed proteins in kidney tissues. The significant down-regulation of ACTN4 may cause the change of actin cytoskeleton of IgAN glomerular podocytes; the significant down-regulation of ACAD may indirectly participate in the occurrence process of abnormal structure and function of IgAN renal tubular epithelial cells by affecting fatty acid metabolism in the cells; and the significant up-regulation of COL1A1 may participate in the accumulation of extracellular matrix in the renal interstitium of IgAN, and play a certain role in promoting the renal interstitial fibrosis. The combination of ACTN4, ACADS and COL1A1 has good prediction efficiency for the diagnosis of the severity of IgAN kidney tissue lesions, and the area under the ROC curve is 0.815, P 0.043. In addition, the immunohistochemical results also confirm the expression trend of the three proteins ACTN4, ACADS and COL1A1 in the corresponding kidney tissue substructures in proteomics.

The invention discloses application of jellyfish and snow rabbits in inhibition of ERK phosphorylation level and MAPK pathway and an evaluation method of the jellyfish and snow rabbits, and relates to the technical field of biological medicines.The method comprises the following steps that 1, a treated jellyfish and snow rabbits breast cancer cell group and a control breast cancer cell group are established; and step 2, respectively dividing the two groups of samples in the step 1 into two parts, fixing one part in paraformaldehyde with the mass concentration of 10%, treating, embedding in paraffin for immunohistochemical analysis, and quickly freezing the other part for transcriptomics analysis and the like. According to the invention, UPLC-MS is adopted to determine the main components of SMM, the influence of SMM on breast cancer (BC) is evaluated through in-vivo experiments, in order to deeply clarify the mechanism, network pharmacology and transcriptomics analysis are integrated, finally, immunohistochemistry (IHC) is adopted to verify and explore the exact breast cancer resisting mechanism of SMM, and a scientific basis is provided for potential clinical application of SMM.

The invention relates to a confining liquid and method for reducing background signals in immunohistochemical detection, and belongs to the technical field of immunodetection, and the confining liquid comprises whey protein and an anionic surfactant. By utilizing the confining liquid provided by the invention, background signals generated on a glass slide can be reduced or even eliminated, and the convenience and accuracy of interpretation of an immunohistochemical detection result are improved.

A system and method of categorizing protein expression in biological cells may include receiving a Whole Slide Image (WSI) of an Immunohistochemistry (IHC) assay of cells, stained with two or more color-specific markers, of two or more respective proteins, and applying a stain separation algorithm on the WSI image, to obtain two or more single¬ channel marker images. Based on the two or more marker images, embodiments may generate an enhanced color image, representing expression of the two or more proteins in the assay, and prompt a user to assign at least one label to at least one respective location in the enhanced color image. Embodiments may then use the at least one label as supervisory information, to train a machine-learning (ML)-based classification model, to classify at least one cell -representative location according to categories of expression of the at least two proteins.

The application relates to the field of immunohistochemical staining, in particular to a DAB buffer and a DAB staining solution kit for DAB color development. The application discloses a DAB buffer for DAB color development, and the main components are hydrogen peroxide, nonylphenol polyoxyethylene ether, magnesium sulfate and trisodium citrate. The metal ions in the DAB buffer can enhance the electron transfer speed between DAB and hydrogen peroxide, and improve the color development sensitivity. The nonylphenol polyoxyethylene ether can stabilize the hydrogen peroxide, so that the hydrogen peroxide can be stored for a longer time and the cost is saved. The application further discloses a DAB staining solution kit, which comprises a blocking agent, a reaction enhancer, an enzyme-labeled polymer IgG, a DAB concentrated solution, a DAB buffer and hematoxylin, and the above-mentioned DAB buffer for DAB color development. The DAB staining solution kit of the application can improve the detection sensitivity of immunohistochemical staining, and can also improve the storage stability of the DAB color development solution and reduce the cost.

The invention discloses an antibody or an antigen binding fragment specifically binding to trop2. The antibody or the antigen binding fragment comprises heavy chain complementarity determining regions HCDR1, HCDR2 and HCDR3, and light chain complementarity determining regions LCDR1, LCDR2 and LCDR3, the amino acid sequence of the HCDR1 is as shown in SEQ ID NO.1, the amino acid sequence of the HCDR2 is as shown in SEQ ID NO.2, the amino acid sequence of the HCDR3 is as shown in SEQ ID NO.3, the amino acid sequence of the LCDR1 is as shown in SEQ ID NO.4, the amino acid sequence of the LCDR2 is as shown in SEQ ID NO.5, and the amino acid sequence of the LCDR3 is as shown in SEQ ID NO.6. The expression condition of trop2 in human breast cancer and pancreatic cancer cell membrane tissue samples can be detected through an immunohistochemical method, and the adjoint diagnostic kit for the humanized trop2 antibody coupling medicine has the advantages of assisting in precise medication and avoiding invalid treatment.

This invention discloses the application of ITPRIPL1 as a biomarker for the diagnosis or prognosis of gastric cancer. Database analysis revealed high expression of ITPRIPL1 in gastric cancer patients. Immunohistochemical staining of samples from clinically diagnosed gastric cancer patients further validated its high expression in gastric cancer tumor cells, with higher ITPRIPL1 expression levels observed in lower-differentiated tumor tissues. This invention provides a novel biomarker for the diagnosis and prognosis of gastric cancer, offering new ideas and directions for immunotherapy of gastric cancer.

The application discloses a marker combination for predicting the curative effect of liposarcoma based on immunohistochemistry, a screening method and a prediction model thereof and a construction method thereof. The application analyzes the tissue phenotype characteristics of a liposarcoma patient by using an immunohistochemistry technology, combines transcriptomic data, screens a suitable marker combination NCF1, CD27, LST1, CD8A and AOAH based on Lasso-logistic regression, and establishes a more accurate immunotherapy curative effect prediction model for the liposarcoma patient.

The present disclosure provides antibodies that specifically bind to protein tyrosine kinase 7 (PTK7), and methods of using such antibodies. In some cases, the PTK7 antibodies are used in an immunohistochemistry (IHC) assay, which can detect the presence of cells expressing PTK7 in a tissue from a patient.

Disclosed herein are methods for identifying a subject as having NSCLC that is predicted or is likely to respond to treatment with an ALK inhibitor, for example crizotinib. The methods include identifying a sample including NSCLC tumor cells as ALK-positive or ALK-negative using immunohistochemistry (IHC) and scoring methods disclosed herein. A subject is identified as having NSCLC likely to respond to treatment with an ALK inhibitor if the sample is identified as ALK-positive and is identified as having NSCLC not likely to respond to treatment with an ALK inhibitor if the sample is identified as ALK-negative. According to certain embodiments of the methods, subjects predicted to respond to an ALK inhibitor may then be treated with an ALK inhibitor such as crizotinib.

The invention belongs to the technical field of biology, and relates to a hybridoma cell strain C8-3-7 and a preparation method thereof. The preservation number of the cell strain C8-3-7 is CCTCC (China Center For Type Culture Collection) No: C202573. The hybridoma cell strain C8-3-7 efficiently expresses the DHX33 antibody and has an infinite proliferation capability. The DHX33 antibody can be specifically combined with DHX33 protein, and can specifically recognize DHX33 protein antigen in ELISA (enzyme-linked immuno sorbent assay) and immunohistochemistry or immunocytochemistry analysis.

The application discloses a BICI scoring system for predicting the curative effect of immunotherapy for metastatic colorectal cancer and application thereof, and belongs to the technical field of biological medicine. The BICI scoring system is based on immunohistochemical detection, integrates four dimensions of angiogenesis, immune checkpoints, TGF-beta signal and immune activation, and is calculated by a formula IHC-BICI=VEGFA+PD-L2+TGFB1x2-CD8 score. Taking 4 points as a cut point, BICI-High and BICI-Low are divided, and a bevacizumab combined with an immune checkpoint inhibitor treatment benefit population is accurately screened. The application also discloses a detection kit containing four specific antibodies, application thereof and a treatment decision method. The scoring system of the application only needs conventional IHC detection, has low cost, excellent prediction effect, is suitable for second-line and above treatment and clinical stratification of MSS / pMMR type metastatic colorectal cancer, and has important clinical application value.

The application provides an immunohistochemical staining image analysis method, including: cutting a plurality of cell nuclei of an immunohistochemical staining image according to a machine learning model; removing pixels belonging to the cell nuclei in the immunohistochemical staining image and removing pixels meeting a color range to obtain a plurality of cytoplasm pixels; distributing the cytoplasm pixels to the cell nuclei according to the positions of the cytoplasm pixels to form a plurality of cells; and calculating a pixel staining score of each pixel in the cells, thereby calculating a cell staining score of the cells. Thus, the staining score of the cells can be objectively and automatically calculated.

The use of AST-3424 in the preparation of a drug for treating a patient with hepatocellular carcinoma. A pathological paraffin block or pathological section of ex-vivo liver tumor tissue from the patient with hepatocellular carcinoma is subjected to immunohistochemical staining to detect the protein expression level of an AKR1C3 enzyme, with the detection result showing an H-score greater than or equal to 200; or the pathological paraffin block or pathological section of ex-vivo liver tumor tissue from the patient with hepatocellular carcinoma is subjected to immunohistochemical staining to detect the protein expression level of an AKR1C3 enzyme, with the detection result showing that the sum of percentages of moderate-intensity staining and high-intensity staining is greater than or equal to 70%. The dosing regimen for AST-3424 is as follows: in each 21-day cycle, administration is performed on day 1 and day 8; the initial dose is 6.0 mg / m2 per administration; and the patient will be permitted to receive treatment for a maximum of 34 cycles.

A method for training a machine learning model and a computing system performing same, wherein the machine learning model is trained to analyze biological tissue slide images stained by a immunohistochemical staining method for staining tissues expressing specific biomarkers and thus can be used to further elaborately analyze expression levels of biomarkers, etc., whereby a determination can be made on pathological specimen images by analyzing expression levels of biomarkers, etc. A method and system for training a machine learning model using training data, corresponding to immunohistochemically stained images, generated from multiple feature vectors calculated based on various staining intensity criteria.

Provided are chimeric or recombinant antibodies (Abs), or antigen-binding fragments thereof, or monomeric or dimeric antigen-binding proteins capable of specifically binding to human LAG-3 polypeptides, including human LAG-3 polypeptides expressed on the surface of lymphocytes, such as activated T cells or tumor-infiltrating lymphocytes (TILs), that have infiltrated tumors, and methods for producing and using the same. In an alternative embodiment, the chimeric or recombinant antibodies (Abs), or antigen-binding fragments thereof, or monomeric or dimeric antigen-binding proteins as provided herein are used for in vitro diagnosis, e.g., in immunohistochemistry (IHC), to diagnose and / or treat cancer, e.g., bladder cancer, urothelial carcinoma, breast cancer, lung cancer, non-small cell lung cancer, kidney cancer, renal clear cell carcinoma, and / or melanoma or malignant melanoma, due to their ability to specifically bind to activated T cells or tumor-infiltrating lymphocytes that have infiltrated tumors.

The application discloses a method suitable for depigmentation of melanoma tissue in immunohistochemical staining, and the method comprises the following steps: after an antigen repairing step in the immunohistochemical staining process, a depigmentation operation is performed; a hydrogen peroxide methanol solution is used as a depigmentation solution; and the depigmentation is performed through heating incubation, wherein the heating temperature is 55 DEG C to 75 DEG C, the volume fraction of the hydrogen peroxide methanol solution is 5% to 15%, and the incubation time is 10 to 20 minutes. The method simplifies the depigmentation process of melanin, is high in efficiency, and does not affect the morphology of tissue cells and IHC staining while achieving depigmentation, and is suitable for depigmentation of melanin cells of melanoma tissue by using a full-automatic immunohistochemical staining instrument, and can realize automatic depigmentation.

The present invention relates generally to antibodies and antigen-binding fragments thereof, in particular those targeting cancer- associated antigens, compositions comprising the same, and methods and uses thereof for detecting cancer-associated antigens in tissues, including prostate cancer tissues. Also provided herein are methods for detecting prostate cancer in a subject, methods for detecting and measuring the severity of prostate cancer in a subject, methods for monitoring the progression of prostate cancer in a subject, methods for determining the likelihood of the presence of prostate cancer in a subject, methods for identifying a subject suffering from prostate cancer who is likely to respond to cancer therapy, methods for predicting the risk of recurrence of prostate cancer in a subject following treatment with a cancer therapy, methods for treating prostate cancer in a subject, methods of stratifying a subject for prostate cancer therapy, uses of anti-cancer agent in the manufacture of a medicament for treating prostate cancer in a subject, and an anti-cancer agent for use in the treatment of prostate cancer in a subject, based upon the detection of specific protein biomarkers with the antibodies described herein. Also contemplated are immunoassays, including immunohistochemistry (IHC) and immunofluorescence (IF), to detect specific protein biomarkers in biological samples. The preferred biomarkers include endosomal proteins, such as Adaptor protein, phosphotyrosine interacting with PH domain and leucine zipper 1 (APPL1), sortilin-1 (SORT1), Syndecan-1 (SDC1).

The application discloses a gene amplification detection method based on nucleic acid mass spectrometry technology, comprising the following steps: setting a target gene region, configuring a reference gene, and confirming experimental primers based on the target gene region and the reference gene; obtaining an experimental sample, performing a primer reaction processing operation based on the experimental primers and the experimental sample, and obtaining a sample to be analyzed; setting an interpretation interval, configuring a sample applicator and a nucleic acid mass spectrometer, performing a data analysis and interpretation operation based on the sample to be analyzed, the interpretation interval, the sample applicator and the nucleic acid mass spectrometer, and obtaining a gene amplification interpretation result; the application can achieve a detection accuracy higher than that of the fluorescence in situ hybridization technology and the immunohistochemical technology in the prior art, a detection throughput higher than that of the fluorescent quantitative PCR technology and the digital PCR technology, a detection cost lower than that of the fluorescent quantitative PCR technology and the digital PCR technology, and a detection time shorter than that of the second-generation sequencing NGS technology.

To provide reliable positive and negative IHC controls that are highly sensitive, specific, and adaptable to a wide range of targets, including targets for which no suitable biological controls exist.SOLUTION: Synthetic controls include a solid antigen / carrier protein gel comprising purified antigen (e.g., in a known amount) and a carrier protein, such as a serum albumin protein (e.g., a serum albumin protein), an egg white protein or a mixture of egg white proteins, gelatin, or polylysine. In some embodiments, the purified antigen is cross-linked to a carrier protein in a solid antigen / carrier protein gel.SELECTED DRAWING: Figure 3-1

The invention relates to the technical field of immune globulins, in particular to a rabbit monoclonal antibody for resisting T cell surface glycoprotein CD1a or an antigen binding fragment of the rabbit monoclonal antibody, a preparation method and application of the rabbit monoclonal antibody. The rabbit monoclonal antibody for resisting the T cell surface glycoprotein CD1a protein is characterized in that amino acid sequences of LCDR1, LCDR2 and LCDR3 of VL of the rabbit monoclonal antibody for resisting the T cell surface glycoprotein CD1a protein are respectively shown as SEQ ID NO.4-6; the amino acid sequences of the HCDR1, the HCDR2 and the HCDR3 of the VH are as shown in SEQ ID NO.8 to SEQ ID NO.10. The invention further provides an immunohistochemical detection kit containing the anti-human CD1a protein rabbit monoclonal antibody and application of the antibody or the kit in immunohistochemical detection, and the anti-human CD1a protein rabbit monoclonal antibody has high specificity and sensitivity, can be applied to marking of CD1a protein in tissue cells, and can be used for immunohistochemical detection. The specificity and the reliability of immunodetection of the CD1a protein are obviously improved.

The present invention describes an automated device for immunohistochemical staining, which includes an antibody dispenser for the localization of specific proteins in histological samples. It also has a receptacle with integrated connectors for radial sample distribution to minimize handling and thus prevent alterations in the results. The automated device for immunohistochemical staining incorporates a container with dividers that allows for the placement of different types of reagents for applying dyes to the samples. The present invention includes a control panel with a control module to fully automate sample processing, and the necessary adjustments for starting the process are made via a screen.

The invention discloses an IgG antibody and application thereof, the IgG antibody is modified from mouse IgM and comprises a heavy chain variable region, a heavy chain constant region, a light chain variable region, a light chain constant region and a tail peptide, the heavy chain constant region comprises mouse IgM heavy chain constant regions CH1 and CH2, and mouse IgG1 heavy chain constant regions H, CH2 and CH3; the amino acid sequences of CDR-H1, CDR-H2 and CDR-H3 in the variable region of the heavy chain are as shown in SEQ ID No.2-4; the amino acid sequences of the CDR-L1, the CDR-L2 and the CDR-L3 in the variable region of the light chain are as shown in SEQ ID No. 6-8; the kit further comprises a mouse IgM J chain. The yield of the modified IgG is increased, the modified IgG can be purified by Protein G and can be stably stored, the same effect as that of mouse anti-human CD15 IgM can be achieved in immunohistochemical staining, and the modified IgG can be more conveniently applied to immunohistochemical detection.